Clinical trial for the safety and efficacy of CD19 CAR-T following autologous hematopoietic stem cell transplantation (ASCT) for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) with High-Risk Prognostic Factors
Histologically confirmed B-cell non-Hodgkin's lymphoma including the following types
diffuse large B-cell lymphoma
high-grade B-cell lymphoma with or without MYC and BLC2 and/or BCL6 rearrangement
transformed lymphoma
History of autologous or allogeneic stem cell transplantation
Active HBV or HCV infection, defined as HBV-DNA or HCV-DNA levels above the normal upper limit, with or without abnormal liver function. Individuals with positive HBsAg or HBcAb should receive antiviral prophylaxis for at least 12 months after CAR-T cells infusion.
Presence of uncontrolled infection, cardio-cerebrovascular disease，coagulopathy, or connective tissue disease.
History of HIV infection
Ruijin Hospital
Lead sponsor